Amblard P, Bazex A, Beylot C, Civatte J, Garrel J, Grupper C, Hincky M, Meynadier J, Privat Y, Thivolet J
Sem Hop. 1980;56(17-18):911-5.
A multicentric trial involving ten dermatological departments was conducted to evaluate the efficacy and tollerance of ANTIBIO-ABEREL (an association of Tretinoin and Erythromycin base) in 347 patients with persistant acne. Complete healing or considerable improvement was obtained in 85% of cases. This new treatment was active against both inflammatory lesions (papules and pustules) and retentional elements (microcysts and open comedones). It was also rapidly active, as very favorable results were obtained in ten weeks or less, in more than half of the cases. The tolerance was remarkable (less than 1% of cases had to interrupt treatment). This product represents an important progress as compared to Tretinoin alone. No other local or systemic therapy, especially long term antibiotherapy, is required.
一项涉及十个皮肤科的多中心试验，旨在评估ANTIBIO - ABEREL（维甲酸和红霉素碱的组合）对347例持续性痤疮患者的疗效和耐受性。85%的病例实现了完全治愈或显著改善。这种新疗法对炎性皮损（丘疹和脓疱）以及潴留性皮损（微囊肿和开放性粉刺）均有效。它起效也很快，超过半数的病例在十周或更短时间内就取得了非常好的效果。耐受性良好（不到1%的病例不得不中断治疗）。与单独使用维甲酸相比，该产品有了重要进展。无需其他局部或全身治疗，尤其是长期抗生素治疗。
